User login
Key clinical point: Rimegepant 75 mg demonstrates favorable efficacy and safety for the treatment of acute migraine compared with the placebo.
Main finding: Rimegepant 75 mg resulted in a significant freedom from pain (20.6% vs. 12.5%; relative risk [RR], 1.70; P less than .001), pain relief (58.6% vs. 44.6%; RR, 1.34; P less than .001), and freedom from the most bothersome symptoms (36.0% vs. 25.1%; RR, 1.44; P less than .001) at 2 hours after dosing compared with the placebo. There was no significant increase in adverse events compared with the placebo.
Study details: A meta-analysis of 4 randomized controlled trials including 3,827 patients with acute migraine.
Disclosures: This study was supported by the Suzhou Health Talents Training Project. The authors declared no conflict of interest.
Citation: Gao B et al. Front Pharmacol. 2020 Jan 24. doi: 10.3389/fphar.2019.01577.
Key clinical point: Rimegepant 75 mg demonstrates favorable efficacy and safety for the treatment of acute migraine compared with the placebo.
Main finding: Rimegepant 75 mg resulted in a significant freedom from pain (20.6% vs. 12.5%; relative risk [RR], 1.70; P less than .001), pain relief (58.6% vs. 44.6%; RR, 1.34; P less than .001), and freedom from the most bothersome symptoms (36.0% vs. 25.1%; RR, 1.44; P less than .001) at 2 hours after dosing compared with the placebo. There was no significant increase in adverse events compared with the placebo.
Study details: A meta-analysis of 4 randomized controlled trials including 3,827 patients with acute migraine.
Disclosures: This study was supported by the Suzhou Health Talents Training Project. The authors declared no conflict of interest.
Citation: Gao B et al. Front Pharmacol. 2020 Jan 24. doi: 10.3389/fphar.2019.01577.
Key clinical point: Rimegepant 75 mg demonstrates favorable efficacy and safety for the treatment of acute migraine compared with the placebo.
Main finding: Rimegepant 75 mg resulted in a significant freedom from pain (20.6% vs. 12.5%; relative risk [RR], 1.70; P less than .001), pain relief (58.6% vs. 44.6%; RR, 1.34; P less than .001), and freedom from the most bothersome symptoms (36.0% vs. 25.1%; RR, 1.44; P less than .001) at 2 hours after dosing compared with the placebo. There was no significant increase in adverse events compared with the placebo.
Study details: A meta-analysis of 4 randomized controlled trials including 3,827 patients with acute migraine.
Disclosures: This study was supported by the Suzhou Health Talents Training Project. The authors declared no conflict of interest.
Citation: Gao B et al. Front Pharmacol. 2020 Jan 24. doi: 10.3389/fphar.2019.01577.